Glatiramer acetate/interferon-β-1a

Glatiramer acetate/interferon-β-1a Reactions 1704, p174 - 2 Jun 2018 Flu-like symptoms and skin rash: 6 case reports In a retrospective, uncontrolled study of 13 patients, six adult patients (three men and three women) were described [ages at the time of reaction onset not clearly stated], who developed flu-like symptoms or skin rash during treatment with glatiramer acetate or interferon-β-1a [Avonex]. The patients, who had uveitis (diagnosed at 32 53 years) and multiple sclerosis (diagnosed at 21 44 years), started receiving immunomodulatory treatment with IM interferon- β-1a 30µg weekly (four patients) or SC glatiramer acetate 20mg daily (two patients). The patients received immunomodulatory therapy for 1 7.5 years. Out of the four patients receiving interferon-β-1a, two patients developed rash whereas the remaining two developed flu-like symptoms. Additionally, amongst the patients receiving glatiramer acetate, one patient developed rash and one patient developed flu-like symptoms. The patient’s treatments were continued [times to reaction onsets and outcomes not stated]. Author comment: "Six of the 13 patients (46%) in immunomodulatory therapy showed secondary effects associated with [interferon-β] or glatiramer acetate, with flu- like symptoms in 3 patients (23%) and skin rash in 3 patients." Velazquez-Villoria D, et al. Efficacy of immunomodulatory therapy with interferon-beta or glatiramer acetate on multiple sclerosis-associated uveitis. Archivos de la Sociedad Espanola de Oftalmologia 92: 273-279, No. 6, Jun 2017. Available from: URL: http://doi.org/10.1016/j.oftal.2016.11.018 [Spanish; summarised from a translation] - Spain 803323563 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Glatiramer acetate/interferon-β-1a

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/glatiramer-acetate-interferon-1a-hr0Ph1og7t
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46817-7
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p174 - 2 Jun 2018 Flu-like symptoms and skin rash: 6 case reports In a retrospective, uncontrolled study of 13 patients, six adult patients (three men and three women) were described [ages at the time of reaction onset not clearly stated], who developed flu-like symptoms or skin rash during treatment with glatiramer acetate or interferon-β-1a [Avonex]. The patients, who had uveitis (diagnosed at 32 53 years) and multiple sclerosis (diagnosed at 21 44 years), started receiving immunomodulatory treatment with IM interferon- β-1a 30µg weekly (four patients) or SC glatiramer acetate 20mg daily (two patients). The patients received immunomodulatory therapy for 1 7.5 years. Out of the four patients receiving interferon-β-1a, two patients developed rash whereas the remaining two developed flu-like symptoms. Additionally, amongst the patients receiving glatiramer acetate, one patient developed rash and one patient developed flu-like symptoms. The patient’s treatments were continued [times to reaction onsets and outcomes not stated]. Author comment: "Six of the 13 patients (46%) in immunomodulatory therapy showed secondary effects associated with [interferon-β] or glatiramer acetate, with flu- like symptoms in 3 patients (23%) and skin rash in 3 patients." Velazquez-Villoria D, et al. Efficacy of immunomodulatory therapy with interferon-beta or glatiramer acetate on multiple sclerosis-associated uveitis. Archivos de la Sociedad Espanola de Oftalmologia 92: 273-279, No. 6, Jun 2017. Available from: URL: http://doi.org/10.1016/j.oftal.2016.11.018 [Spanish; summarised from a translation] - Spain 803323563 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off